Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Kovaltry

    - PMLiVE

    Novo Nordisk’s Alhemo approved by FDA for expanded haemophilia use

    The rare bleeding disorder affects approximately 800,000 people globally

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    - PMLiVE

    Pfizer shares positive phase 3 results for haemophilia A and B therapy Hympavzi

    Around 20% and 3% of haemophilia A and B patients, respectively, develop inhibitors

    - PMLiVE

    Pfizer’s Hympavzi granted MHRA approval to treat haemophilia A and B

    More than 11,800 people were living with the genetic blood disorders in the UK in 2023/2024

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    - PMLiVE

    Novo Nordisk’s haemophilia A therapy Mim8 shows promise in late-stage study

    The inherited bleeding disorder accounts for up to 85% of the 1,125,000 global haemophilia cases

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Bayer symbol

    Bayer’s non-hormonal menopause drug shows promise in phase 3 breast cancer trial

    Breast cancer patients can experience vasomotor symptoms as a result of adjuvant endocrine therapy

    - PMLiVE

    Novo Nordisk invests $1.2bn to establish rare disease production facility in Denmark

    The site will be designed to accommodate multiple product types within rare diseases

    - PMLiVE

    Pfizer’s Hympavzi receives EC approval to treat haemophilia A and B patients

    The genetic blood disorder affects more than 800,000 people globally

    - PMLiVE

    Novo Nordisk’s Alhemo recommended by CHMP for haemophilia A and B

    The rare bleeding disorder affects approximately 1,125,000 people globally

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links